US4339426A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Bleomycin analog
Assignee: CALIFORNIA A CORP OF CA, University of, Regents of
•
Filing: 1980-03-18
•
Granted: 1982-07-13
•
Expires: 2000-03-18
Abstract
Abstract Bleomycin's affinity for tumorous tissue and its ability to complex with cobalt has lead to its use in vivo as a complex with 57Cobalt. This complex has given excellent tumor images and has been useful for diagnostic purposes. Unfortunately, 57Co has the undesirable property of a 270 day half-life. The present invention provides a bleomycin analog which has a powerful meal-chelating substituent covalently bound to and chemically modifying a bleomycin. However, the inclusion of this chelating substituent in the bleomycin analog does not significantly modify the in vivo biological properties thereof with respect to unmodified bleomycin. The inventive bleomycin analog forms stable chelates with a variety of metal ions, and is particularly useful when labelled with radionuclides having short half-lives. So labelled, the bleomycin analog may be utilized for diagnostic purposes.
Inventors
- 👤 Claude F. Meares
- 👤 Leslie D. Anderson
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 20:19
CPC Classifications
C; C07; C07K; C07K9/00; C07K9/001; C07K9/003; A; A61; A61K; A61K51/00; A61K51/02; A61K51/04; A61K51/08; A61K51/088; A61K51/12; A61K2123/00; Y; Y10; Y10S; Y10S930/00; Y10S930/01; Y10S930/19
Claims Analysis
Total Claims: 24
Claim 1
Independent Claim
41 words
A bleomycin analog comprising: a modified bleomycin, said bleomycin being modified in one region thereof, said one region being of the structure ##STR14## wherein R 1 includes a chelating substituent with a plurality of functional groups capable of chelating metal ions.
Claim 2
Dependent Claim
41 words
A bleomycin analog comprising: a modified bleomycin, said bleomycin being modified in one region thereof, said one region being of the structure ##STR14## wherein R 1 includes a chelating substituent with a plurality of functional groups capable of chelating metal ions.
Claim 3
Dependent Claim
18 words
The bleomycin analog as in claim 1, wherein said chelating substituent is an EDTA or a DTPA derivative.
Claim 4
Dependent Claim
36 words
The bleomycin analog as in claim 1 wherein said chelating substituent includes a 1-substituted EDTA moiety of the structure ##STR15## and at least three of R 2 -R 5 are carboxylate moieties as said functional groups.
Claim 5
Dependent Claim
33 words
The bleomycin analog as in claim 3 wherein three of R 2 -R 5 are carboxylate moieties as said functional groups, and one of said R 2 -R 5 is --CH 2 OH.
Claim 6
Dependent Claim
19 words
The bleomycin analog as in claim 1 wherein said chelating substituent is a para-substituted, 1-phenyl or 1-benzyl EDTA derivative.
Claim 7
Dependent Claim
15 words
The bleomycin analog as in claim 1 wherein said chelating substituent is a 1-(p-acetamidophenyl)-EDTA derivative.
Claim 8
Dependent Claim
22 words
The bleomycin analog as in claim 1 wherein said modified bleomycin has another region thereof which is complexed with cobalt or copper.
Claim 9
Dependent Claim
17 words
The bleomycin analog as in claim 1 wherein said functional groups are chelated with a metal ion.
Claim 10
Dependent Claim
21 words
The bleomycin analog as in 2 wherein said EDTA or DTPA derivative of said chelating substituent is chelated with a radionuclide.
Claim 11
Dependent Claim
21 words
The bleomycin analog as in 2 wherein said EDTA or DTPA derivative of said chelating substituent is chelated with a radionuclide.
Claim 12
Dependent Claim
26 words
The bleomycin analog as in claim 9 wherein said radionuclide emits gamma radiation and has a half-life ranging from about three hours to about three days.
Claim 13
Dependent Claim
21 words
The bleomycin analog as in claim 9 wherein said radionuclide is selected from the group consisting of In-111, Tc-99m and Ga-68.
Claim 14
Dependent Claim
21 words
The bleomycin analog as in claim 2 wherein said EDTA or DTPA derivative of said chelating substituent is chelated with In-111.
Claim 15
Dependent Claim
36 words
A bleomycin analog comprising: a bleomycin A 2 having a modified terminal amine of the structure ##STR16## wherein R 1 is a chelating substituent with a plurality of functional groups capable of chelating a metal ion.
Claim 16
Dependent Claim
36 words
A bleomycin analog comprising: a bleomycin A 2 having a modified terminal amine of the structure ##STR16## wherein R 1 is a chelating substituent with a plurality of functional groups capable of chelating a metal ion.
Claim 17
Dependent Claim
15 words
The bleomycin analog as in claim 13 wherein said chelating substituent is an EDTA analog.
Claim 18
Dependent Claim
36 words
The bleomycin analog as in claim 13 wherein said chelating substituent includes a 1-substituted EDTA moiety of the structure ##STR17## and at least three of R 2 -R 5 are carboxylate moieties as said functional groups.
Claim 19
Dependent Claim
33 words
The bleomycin analog as in claim 15 wherein three of R 2 -R 5 are carboxylate moieites as said functional groups and one of said R 2 -R 5 is --CH 2 OH.
Claim 20
Dependent Claim
19 words
The bleomycin analog as in claim 15 wherein said chelating substituent is a para-substituted, 1-phenyl or 1-benzyl EDTA derivative.
Claim 21
Dependent Claim
17 words
The bleomycin analog as in claim 13 wherein said functional groups are chelated with a metal ion.
Claim 22
Independent Claim
89 words
A method of localizing tumors in mammals comprising: providing a quantity of a biologically active bleomycin analog having one region with a 1-substituted EDTA derivative or a DTPA derivative; exposing said quantity of bleomycin analog to a source of gamma radiation emitting radionuclide, to chelate said radionuclide with amino groups and carboxylate groups of said EDTA or DTPA derivative and to form a radiolabelled bleomycin analog; injecting a dose of said radiolabelled bleomycin analog into a circulatory system of a mammal; and, scanning the mammal with a gamma detector.
Claim 23
Independent Claim
89 words
A method of localizing tumors in mammals comprising: providing a quantity of a biologically active bleomycin analog having one region with a 1-substituted EDTA derivative or a DTPA derivative; exposing said quantity of bleomycin analog to a source of gamma radiation emitting radionuclide, to chelate said radionuclide with amino groups and carboxylate groups of said EDTA or DTPA derivative and to form a radiolabelled bleomycin analog; injecting a dose of said radiolabelled bleomycin analog into a circulatory system of a mammal; and, scanning the mammal with a gamma detector.
Claim 24
Dependent Claim
20 words
The method as in claim 19 wherein said radionuclides are selected from the group consisting of In-111, Tc-99m and Ga-68.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1985-07-12 | 1986-01-11 | 1986-07-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1989-07-12 | 1990-01-11 | 1990-07-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1993-07-12 | 1994-01-11 | 1994-07-13 | $7700.00 | Window Closed / Lapsed |